Loading...
NPI 1366539595 · Bowie, MD · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Annapath, Inc is a clinical medical laboratory provider located in Bowie, Maryland. This profile covers 39 Medicare and 15 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Annapath, Inc |
| Address | 4801 Tesla Dr Ste Hjkl&m |
| City | Bowie |
| State | MD |
| ZIP | 20715 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | October 9, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $6.2M |
| Medicaid | $2.4M |
ANNAPATH, INC’s billing mix is consistent with a high-volume surgical pathology and immunohistochemistry laboratory: its largest Medicare-volume codes are 88305 (surgical pathology level IV, 42.7K claims, $1.6M revenue), 88313 (special staining technical work, 20.1K claims, $1.4M revenue), and 88342 (initial single antibody stain, 17.8K claims, $1.2M revenue). These codes and claim volumes indicate primary operations centered on tissue processing, special stains, and antibody-based diagnostic testing rather than routine chemistry or hematology as the core business line.
Revenue concentration on Medicare is highly focused: the precomputed top-3 Medicare codes account for 67.4% of the provider’s total Medicare revenue. That concentration shows the business is heavily dependent on a small set of pathology/IHC procedures for most of its $6.2M in Medicare receipts.
Medicaid billing mirrors Medicare in service mix and concentration: the precomputed top-3 Medicaid codes account for 68.0% of the provider’s total Medicaid revenue, with 88305 ($657.9K), 88313 ($536.2K), and 88342 ($465.4K) driving the bulk of the $2.4M in Medicaid revenue. This indicates the same surgical pathology and immunostain services are the primary revenue drivers across both payers, not a divergent payer-specific service portfolio.
Competitively, the provider is an outsized volume player on national Medicare benchmarks for core pathology/IHC codes: 88313 ranks #2 of 6757 providers and is labeled an "extreme outlier," 88342 ranks #4 of 11370 (100th percentile), and 88305 ranks #21 of 14580 (100th percentile). These rank/percentile positions indicate ANNAPATH operates at volumes far above typical national peers for these specific pathology services.
In-state (Maryland) Medicaid rankings show clear dominance in the same specialty areas: 88313, 88342, and 88312 each rank #1 among in-state peers for Medicaid volume, and 88305 ranks #3 in-state. Those positions indicate ANNAPATH is a major statewide provider for surgical pathology and staining services, capturing a leading share of Medicaid pathology billing in Maryland.
Despite the concentration in high-value pathology and IHC codes, the provider also bills routine laboratory tests at much smaller levels (examples on Medicare: 84153 PSA $38.9K, 85025 CBC $1.9K, 80053 CMP $1.8K). These smaller revenue lines suggest ancillary routine testing is present but not a primary revenue driver compared with the dominant surgical pathology and staining services.
The provider’s tenure (NPI enumerated 2006-10-09, ~20 years ago) combined with consistently high-volume rankings suggests an established referral base and operational continuity supporting specialized pathology throughput rather than a recent or transient testing operation. Longevity plus extreme-volume rankings strengthen the interpretation of a sustained specialty lab business model.
Code-level statistical labels reinforce the picture of an atypically large specialty lab: multiple top codes are explicitly noted as "extreme outlier" or "100th percentile" nationally for Medicare and as top-ranked in-state for Medicaid, while many other billed codes are described as "typical, unremarkable volume." This mix points to a deep specialization in complex pathology/IHC services with routine testing as a minor adjunct.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
39 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 42,730 | $40 | $1.6M |
| 88313 | The lab analyst performs the technical lab steps to stain a specimen for Group II identification, for example an iron stain or trichrome stain. A qualified provider, typically a pathologist,… | 20,110 | $70 | $1.4M |
| 88342 | The lab analyst applies an initial single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 17,810 | $70 | $1.2M |
| 88312 | The lab analyst performs the technical lab steps to stain a specimen with a special stain. This code applies to Group I for microorganisms. A qualified provider, typically a pathologist, interprets… | 13,000 | $90 | $1.1M |
| 88341 | The lab analyst applies an additional single antibody stain on a slide or slides prepared from the same patient specimen as the initial antibody stain, such as tumor tissue. Then a qualified… | 11,120 | $60 | $656.1K |
| 88120 | The lab analyst performs a technical lab test on a urinary tract specimen using in situ hybridization and three to five molecular probes for manual morphometric analysis, looking at the number and… | 90 | $550 | $50.1K |
| 84153 | The lab analyst performs testing for total prostate specific antigen, PSA, typically on serum or plasma samples using laboratory analyzers. PSA is a protein the prostate gland produces, and… | 2,160 | $20 | $38.9K |
| G0416 | Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 190 | $180 | $34.5K |
| 88173 | The lab analyst performs the technical lab test to analyze a cytopathology specimen from a fine needle aspirate and then interprets and reports the results. | 210 | $140 | $30K |
| 84403 | The lab analyst performs a test to measure total testosterone, typically in patient serum. | 570 | $30 | $14.3K |
Showing 1–10 of 39
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 39 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
15 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 24,370 | $30 | $657.9K |
| 88313 | The lab analyst performs the technical lab steps to stain a specimen for Group II identification, for example an iron stain or trichrome stain. A qualified provider, typically a pathologist,… | 12,470 | $40 | $536.2K |
| 88342 | The lab analyst applies an initial single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 16,620 | $30 | $465.4K |
| 88312 | The lab analyst performs the technical lab steps to stain a specimen with a special stain. This code applies to Group I for microorganisms. A qualified provider, typically a pathologist, interprets… | 10,200 | $40 | $397.6K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 4,010 | $50 | $208.3K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1,500 | $50 | $80.9K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 5,430 | $10 | $65.2K |
| 88341 | The lab analyst applies an additional single antibody stain on a slide or slides prepared from the same patient specimen as the initial antibody stain, such as tumor tissue. Then a qualified… | 1,740 | $10 | $20.8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 2,070 | $1 | $6.2K |
| 87086 | Culture, bacterial; quantitative, colony count, urine. | 390 | $1 | $390 |
Showing 1–10 of 15
How this provider's Medicaid billing volume and revenue compare to other Maryland providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Maryland median
15 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 33 | 80 | 500 | $70 | $691.2K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 9 | 30 | 710 | $40 | $267.8K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 3 | 120 | 850 | $60 | $186.4K |
| 88313 | The lab analyst performs the technical lab steps to stain a specimen for Group II identification, for example an iron stain or trichrome stain. A qualified provider, typically a pathologist,… | 1 | 40 | 260 | $60 | $73.4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 23 | 50 | 1,730 | $10 | $57.8K |
| 88342 | The lab analyst applies an initial single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 1 | 70 | 340 | $50 | $57.5K |
| 84153 | The lab analyst performs testing for total prostate specific antigen, PSA, typically on serum or plasma samples using laboratory analyzers. PSA is a protein the prostate gland produces, and… | 16 | 20 | 700 | $10 | $51.9K |
| 88312 | The lab analyst performs the technical lab steps to stain a specimen with a special stain. This code applies to Group I for microorganisms. A qualified provider, typically a pathologist, interprets… | 1 | 40 | 100 | $60 | $44.7K |
| 87086 | Culture, bacterial; quantitative, colony count, urine. | 48 | 70 | 800 | $10 | $30.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 7 | 100 | 280 | $10 | $26.4K |
Showing 1–10 of 15
Other providers in the same ZIP code as Annapath, Inc, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.